Axitinib
Translocation Renal Cell Carcinoma
Stephanie BergSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
7 Active assets in the Translocation Renal Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bms-907351 Memorial Sloan Kettering Cancer Center | Phase 2 | B |
Palbociclib Stephanie Berg | Phase 2 | CCC |
Ipilimumab Bradley A. McGregor, MD | Phase 2 | CCC |
Nivolumab Instituto do Cancer do Estado de São Paulo | Phase 2 | CCC |
Abemaciclib Memorial Sloan Kettering Cancer Center | Phase 1/2 | CC |
Cytokine Induced Memory-Like Natural Killer Cells Dana-Farber Cancer Institute | Early Phase 1 | C |
Sasanlimab Stephanie Berg | Phase 2 | C |
Same molecule, other indications
Axitinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →